# MAGEA12

## Overview
MAGEA12 is a gene that encodes the protein MAGE family member A12, which is part of the type I melanoma antigen (MAGE) family. This family is characterized by its involvement in various cellular processes, including protein-protein interactions and ubiquitination, which are crucial for maintaining cellular homeostasis and genomic integrity (Lee2017A). MAGEA12 is primarily expressed in germ cells, particularly in the testis, where it plays a significant role in spermatogenesis and germ cell development (Lee2017A). The protein is also implicated in cancer biology, acting as a cancer-testis antigen with altered expression in several malignancies, including hepatocellular carcinoma and bladder cancer, where it is associated with poor prognosis (Verma2024Melanoma; Li2020A). MAGEA12's interactions with other MAGE proteins and its regulation by ubiquitin ligases highlight its potential as a biomarker and therapeutic target in oncology (Ravichandran2019Regulation; Verma2024Melanoma).

## Structure
MAGEA12, a member of the MAGE (Melanoma Antigen Gene) family, is characterized by a primary structure consisting of 314 amino acids. The MAGE homology domain (MHD), a central feature of MAGE proteins, begins at residue 109 and spans approximately 165-171 amino acids. This domain is predicted to contain at least four potential α-helical domains and five regions of β-sheet structure, although the precise secondary structure remains unresolved (Barker2002The).

The MHD is a tandem-winged helix motif, which may undergo allosteric modifications to facilitate protein-protein interactions, a key aspect of its function (Alsalloum2023The). MAGEA12, like other MAGE proteins, is involved in binding interactions that are central to its functionality, particularly in the context of cancer and immune response (Florke2020Emerging).

MAGEA12 is part of subfamily II within the MAGE-A gene family, and its coding region is contained in the last exon, with several alternatively spliced untranslated exons preceding it. This gene exhibits a unique splicing pattern, creating a chimeric exon, 1-0, due to deletions that remove the intron and adjacent parts of exons 1 and 0 (Artamonova2004Evolution).

## Function
MAGEA12, a member of the type I MAGE family, is primarily expressed in germ cells, particularly in the testis, where it plays a significant role in germ cell development and spermatogenesis. MAGE-A proteins, including MAGEA12, are involved in the regulation of spermatogenesis by being expressed in spermatogonia and primary spermatocytes, indicating their role in the early stages of sperm cell development. The expression of these proteins is highly regulated, and they are crucial for maintaining germ cell viability, as evidenced by mouse models where deletion of several Mage-a genes resulted in reduced testis size and increased apoptosis of germ cells (Lee2017A).

MAGEA12 is also involved in forming complexes with E3 RING ubiquitin ligases, known as MAGE-RING ligases (MRLs). These complexes regulate ubiquitination processes, which are critical for various cellular functions, including protein degradation, endocytosis, DNA repair, and activation of transcription factors. This regulation is essential for maintaining cellular homeostasis and genomic integrity (Lee2017A). MAGEA12's involvement in these molecular processes suggests its broader physiological roles beyond its initial identification as a cancer-testis antigen.

## Clinical Significance
MAGEA12 is implicated in various cancers due to its altered expression levels. In hepatocellular carcinoma (HCC), higher expression of MAGEA12 is associated with a worse prognosis, with a hazard ratio of 1.89, indicating a nearly two-fold increase in the risk of poor outcomes for patients with elevated expression levels (Li2020A). MAGEA12 is also significantly up-regulated in HCC tissues compared to non-tumor tissues, suggesting its potential as a biomarker for diagnosis and treatment (Li2020A).

In bladder cancer, MAGEA12 shows significant differences in expression levels compared to normal tissues. Elevated levels of MAGEA12 are linked to poor survival, with a statistically significant hazard ratio, indicating its potential as a diagnostic biomarker and its role in assessing disease aggressiveness (Verma2024Melanoma).

MAGEA12 is part of the MAGE-A gene family, which is known for its role in cancer progression and metastasis. These genes are often overexpressed in various cancers, contributing to tumor growth, proliferation, migration, and invasion while inhibiting apoptosis. This abnormal expression is frequently due to epigenetic dysregulation, such as DNA hypomethylation, which is associated with poor survival outcomes in certain cancers (Poojary2020Prognostic).

## Interactions
MAGEA12, a member of the melanoma antigen family, is involved in significant protein-protein interactions that influence cancer progression. The MAGEA family, including MAGEA12, interacts with other MAGE proteins such as MAGEA2B, MAGEB10, and MAGEB2. These interactions are crucial as both MAGEA and MAGEB families share the MAGE domain, which affects the tumor microenvironment and promotes cell proliferation (Verma2024Melanoma).

MAGEA12 is also regulated by the CRL4-DCAF12 E3 ubiquitin ligase, which targets proteins with a specific degron motif at their C-terminus. This regulation is particularly relevant under conditions of nutrient deprivation, where the degradation of MAGEA12 is mediated by the ubiquitin-proteasome system. The CRL4-DCAF12 ligase plays a critical role in this process, as knockdown of DCAF12 diminishes the degradation of MAGEA12, indicating its importance in the regulation of MAGEA12 stability (Ravichandran2019Regulation).

While specific interactions of MAGEA12 with other proteins or nucleic acids are not detailed extensively, its involvement in these regulatory pathways and interactions with other MAGE proteins suggests a role in modulating cellular processes related to cancer progression.


## References


[1. (Barker2002The) Philip A. Barker and Amir Salehi. The mage proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. Journal of Neuroscience Research, 67(6):705–712, February 2002. URL: http://dx.doi.org/10.1002/jnr.10160, doi:10.1002/jnr.10160. This article has 243 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jnr.10160)

[2. (Artamonova2004Evolution) Irena I. Artamonova and Mikhail S. Gelfand. Evolution of the exon–intron structure and alternative splicing of the mage-a family of cancer/testis antigens. Journal of Molecular Evolution, 59(5):620–631, November 2004. URL: http://dx.doi.org/10.1007/s00239-004-2654-3, doi:10.1007/s00239-004-2654-3. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00239-004-2654-3)

[3. (Florke2020Emerging) Rebecca R. Florke Gee, Helen Chen, Anna K. Lee, Christina A. Daly, Benjamin A. Wilander, Klementina Fon Tacer, and Patrick Ryan Potts. Emerging roles of the mage protein family in stress response pathways. Journal of Biological Chemistry, 295(47):16121–16155, November 2020. URL: http://dx.doi.org/10.1074/jbc.rev120.008029, doi:10.1074/jbc.rev120.008029. This article has 47 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.rev120.008029)

[4. (Alsalloum2023The) Alaa Alsalloum, Julia Shevchenko, and Sergey Sennikov. The melanoma-associated antigen family a (mage-a): a promising target for cancer immunotherapy? Cancers, 15(6):1779, March 2023. URL: http://dx.doi.org/10.3390/cancers15061779, doi:10.3390/cancers15061779. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers15061779)

[5. (Li2020A) Rong Li, Jiao Gong, Cuicui Xiao, Shuguang Zhu, Zhongying Hu, Jinliang Liang, Xuejiao Li, Xijing Yan, Xijian Zhang, Danyang Li, Wei Liu, Yutian Chong, and Yusheng Jie. A comprehensive analysis of the mage family as prognostic and diagnostic markers for hepatocellular carcinoma. Genomics, 112(6):5101–5114, November 2020. URL: http://dx.doi.org/10.1016/j.ygeno.2020.09.026, doi:10.1016/j.ygeno.2020.09.026. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ygeno.2020.09.026)

[6. (Ravichandran2019Regulation) Ramya Ravichandran, Kiran Kodali, Junmin Peng, and Patrick Ryan Potts. Regulation of <scp>mage</scp> ‐a3/6 by the <scp>crl</scp> 4‐ <scp>dcaf</scp> 12 ubiquitin ligase and nutrient availability. EMBO reports, May 2019. URL: http://dx.doi.org/10.15252/embr.201847352, doi:10.15252/embr.201847352. This article has 29 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.15252/embr.201847352)

[7. (Lee2017A) Anna K. Lee and Patrick Ryan Potts. A comprehensive guide to the mage family of ubiquitin ligases. Journal of Molecular Biology, 429(8):1114–1142, April 2017. URL: http://dx.doi.org/10.1016/j.jmb.2017.03.005, doi:10.1016/j.jmb.2017.03.005. This article has 101 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jmb.2017.03.005)

[8. (Poojary2020Prognostic) Manish Poojary, Padacherri Vethil Jishnu, and Shama Prasada Kabekkodu. Prognostic value of melanoma-associated antigen-a (mage-a) gene expression in various human cancers: a systematic review and meta-analysis of 7428 patients and 44 studies. Molecular Diagnosis &amp; Therapy, 24(5):537–555, June 2020. URL: http://dx.doi.org/10.1007/s40291-020-00476-5, doi:10.1007/s40291-020-00476-5. This article has 20 citations.](https://doi.org/10.1007/s40291-020-00476-5)

[9. (Verma2024Melanoma) Shiv Verma, Diya Swain, Prem Prakash Kushwaha, Smit Brahmbhatt, Karishma Gupta, Debasish Sundi, and Sanjay Gupta. Melanoma antigen family a (mage a) as promising biomarkers and therapeutic targets in bladder cancer. Cancers, 16(2):246, January 2024. URL: http://dx.doi.org/10.3390/cancers16020246, doi:10.3390/cancers16020246. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers16020246)